Amgen Inc (AMGN) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,32%	1 100,57	−3,53	−0,32%	—	1 104,10	1 103,92	1 108,75	1 097,16	—	—
SIXC Communications SIXC Communications	SIXC +0,16%	605,15	+0,99	+0,16%	—	604,16	604,16	610,19	604,12	—	—
SIXE Energy SIXE Energy	SIXE −0,22%	1 195,19	−2,62	−0,22%	—	1 197,81	1 200,58	1 213,07	1 192,02	—	—
SIXI Industrials SIXI Industrials	SIXI −0,03%	1 739,91	−0,50	−0,03%	—	1 740,41	1 739,55	1 750,27	1 730,60	—	—
SIXM Financials SIXM Financials	SIXM +0,65%	638,56	+4,12	+0,65%	—	634,44	633,13	639,87	633,01	—	—
SIXR Staples SIXR Staples	SIXR −1,11%	831,57	−9,33	−1,11%	—	840,90	839,53	841,73	831,10	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,82%	213,36	−1,77	−0,82%	—	215,13	215,13	215,85	213,24	—	—
SIXT Technology SIXT Technology	SIXT +0,17%	3 234,18	+5,47	+0,17%	—	3 228,71	3 225,62	3 235,43	3 198,95	—	—
SIXU Utilities SIXU Utilities	SIXU −0,02%	935,65	−0,22	−0,02%	—	935,87	938,37	942,00	935,65	—	—
SIXV Health care SIXV Health care	SIXV −0,54%	1 449,26	−7,86	−0,54%	—	1 457,12	1 452,74	1 466,88	1 449,18	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,72%	2 382,45	−17,39	−0,72%	—	2 399,84	2 389,71	2 394,61	2 371,22	—	—

Inntekt Q1 2026 • om 2 dager

Se detaljene

AMGN:NASDAQ

Amgen Inc

340,15 USD

−1,28%

(−4,40) 1 D

343,50 USD

+0,98% (+3,35)

Før børsåpning

Stengt: 27. apr., 16:00:03 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for AMGN …

Åpne

342,35 USD

Høy

348,04 USD

Lav

339,98 USD

Markedsverdi

183,57 mrd.

Snittvolum

2,60 mill.

Volum

5,74k

Utbytte

2,96 %

Kvartalsvis utbytte

2,52 USD

Første dato etter utbytte

15. mai 2026

P/E-forhold

23,91

52 u høy

391,29 USD

52 u lav

261,43 USD

EPS

14,23 USD

Beta

0,47

Utestående aksjer

539,69 mill.

Antall ansatte

32k

Relaterte aksjer

Alnylam Pharmaceuticals, Inc.

Nyhetssaker

Fra kilder på nettet

GuruFocus

for 55 minutter siden

AMGN Faces Withdrawal Proposal for Tavneos Amid Effectiveness Co

MarketBeat

for 1 time siden

Amgen Inc. $AMGN Shares Purchased by Mitsubishi UFJ Trust & Banking Corp

CNBC

for 19 timer siden

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Yahoo Finance

for 23 timer siden

Exploring Analyst Estimates for Amgen (AMGN) Q1 Earnings, Beyond Revenue and EPS

Profil

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000. Wikipedia

Om Amgen Inc

Administrerende direktørRobert A. Bradway

Ansatte31,5k

Grunnlagt8. apr. 1980

HovedkontorThousand Oaks, California, USA

Sektor-

Nettstedamgen.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	8,15 mrd.	9,18 mrd.	9,56 mrd.	9,87 mrd.
Varekostnad	2,60 mrd.	2,67 mrd.	2,74 mrd.	2,68 mrd.
Direkte driftskostnader	2,60 mrd.	2,67 mrd.	2,74 mrd.	2,68 mrd.
Utgifter til forskning og utvikling	1,49 mrd.	1,74 mrd.	1,90 mrd.	2,14 mrd.
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	1,69 mrd.	1,69 mrd.	1,72 mrd.	1,95 mrd.
Driftskostnader	3,20 mrd.	3,50 mrd.	3,55 mrd.	4,18 mrd.
Totale driftskostnader	5,81 mrd.	6,18 mrd.	6,29 mrd.	6,85 mrd.
Driftsinntekter	2,34 mrd.	3,00 mrd.	3,26 mrd.	3,01 mrd.
Andre ikke-operasjonelle inntekter	−36,00 mill.	−113,00 mill.	181,00 mill.	143,00 mill.
EBT inkludert uvanlige elementer	1,97 mrd.	1,57 mrd.	3,92 mrd.	1,51 mrd.
EBT uten uvanlige elementer	1,66 mrd.	2,37 mrd.	2,72 mrd.	2,51 mrd.
Kostnad for inntektsskatt	243,00 mill.	136,00 mill.	705,00 mill.	181,00 mill.
Faktisk avgiftssats	12,32 %	8,67 %	17,98 %	11,96 %
Andre driftskostnader	30,00 mill.	68,00 mill.	−71,00 mill.	82,00 mill.
Nettoinntekt	1,73 mrd.	1,43 mrd.	3,22 mrd.	1,33 mrd.
Netto fortjenestemargin	21,23 %	15,60 %	33,65 %	13,51 %
Resultat per aksje	4,90	6,02	5,64	5,29
Rente- og investeringsinntekter	-	-	-	408,00 mill.
Rentekostnader	−723,00 mill.	−694,00 mill.	−685,00 mill.	−1,06 mrd.
Netto rentekostnader	−723,00 mill.	−694,00 mill.	−685,00 mill.	−653,00 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	3,73 mrd.	4,34 mrd.	4,57 mrd.	4,02 mrd.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning